文献速递浆细胞疾病

比较多发性骨髓瘤合并管型肾病所致急性肾损伤患者双药与三药硼替佐米方案随机试验

Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.
PubMed 文献 · J Clin Oncol · 2020-06-23

这项多中心对照试验将无需透析的初发骨髓瘤管型肾病合并急性肾损伤患者随机分为硼替佐米联合地塞米松(BD)组或再加环磷酰胺(C-BD)组,每组92例。3个月肾脏缓解率两组无差异(BD组41例 vs C-BD组47例,RR 0.87,P=0.46),C-BD未在肾脏恢复上显示优于BD的获益。

要点

  • 3个月肾脏缓解率BD组41例 vs C-BD组47例,RR 0.87,P=0.46,无显著差异
  • 游离轻链下降≥90%及以上者BD组36例 vs C-BD组47例,RR 0.76,P=0.10
  • 严重不良事件BD组30例 vs C-BD组40例

核心结论

  • 这项随机研究未显示C-BD较BD在无需透析的初发管型肾病患者肾脏恢复方面有任何获益。
  • 加用环磷酰胺未能充分改善疗效-毒性平衡。
  • 合并急性肾损伤的骨髓瘤患者体质脆弱,双药或三药方案的指征应根据虚弱程度调整。

研究设计与样本

  • 多中心对照试验,在给予对症措施和大剂量地塞米松后,将患者随机分配至硼替佐米联合地塞米松(BD)组或BD联合环磷酰胺(C-BD)组。
  • 每组纳入92例患者。
  • 对3个周期后血清游离轻链(sFLC)下降<50%的患者,BD组加用环磷酰胺强化,C-BD组加用沙利度胺强化。

主要发现

  • 随机分组时两组特征相似,中位年龄68岁,血清肌酐水平BD组305.5 µmol/L、C-BD组273.5 µmol/L。
  • 3个月时肾脏缓解率(主要终点)无差异:BD组41例缓解 vs C-BD组47例缓解,RR 0.87,P=0.46。
  • 达到非常好的部分缓解(游离轻链下降≥90%)及以上者BD组36例 vs C-BD组47例,RR 0.76,P=0.10。
  • 1个周期化疗后sFLC≤500 mg/L者BD组69例 vs C-BD组67例。
  • 严重不良事件BD组30例 vs C-BD组40例;12个月时死亡19例(BD组9例 vs C-BD组10例),其中骨髓瘤进展死亡10例(BD组6例 vs C-BD组4例)、感染死亡3例(BD组0例 vs C-BD组3例)。

临床怎么用

  • 原文结论指出,双药或三药方案的指征应根据患者虚弱程度调整,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS: After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone (BD), or BD plus cyclophosphamide (C-BD). In patients with < 50% reduction of serum free light chains (sFLCs) after 3 cycles, chemotherapy was reinforced with either cyclophosphamide (BD group) or thalidomide (C-BD group). RESULTS: Ninety-two patients were enrolled in each group. At random assignment, characteristics of the 2 groups were similar, including median age (68 years) and serum creatinine level (305.5 and 273.5 µmol/L in BD and C-BD group, respectively). At 3 months, renal response rate (primary end point) was not different (41 v 47 responders in the BD and C-BD groups, respectively; relative risk [RR], 0.87; P = .46). Very good partial response (free light chain reduction ≥ 90%) or more was achieved in 36 and 47 patients, respectively (RR, 0.76; P = .10). After 1 cycle of chemotherapy, 69 in the BD group and 67 patients in the C-BD group had achieved sFLC level ≤ 500 mg/L. Serious adverse events were recorded in 30 and 40 patients, respectively. At 12 months, 19 patients had died (9 in the BD group v 10 in the C-BD group), including 10 (6 in the BD group and 4 in the C-BD group) from myeloma progression and 3 (0 in the BD group and 3 in the C-BD group) from infection. Within median follow-up of 27 months, 43 and 42 patients switched to new therapy, respectively. Overall, 50 patients (24 in the BD group and 26 in the C-BD group) had died. CONCLUSION: This randomized study did not show any benefit of C-BD compared with BD on renal recovery of patients with initial CN not requiring dialysis. Adding cyclophosphamide did not sufficiently improve the efficacy-toxicity balance. Patients with myeloma with AKI are fragile, and indication for doublet or triplet regimen should be adapted to frailty.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bridoux F, Arnulf B, Karlin L, et al. Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. J Clin Oncol. 2020. PMID: 32574117. doi:10.1200/JCO.20.00298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。